Physician profile
Michael Christopher Moy
NPI 1164623708
$2,860.85
in general payments reported to CMS, 2019-2025
14 companies · $950 in 2025
The $950 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $516 · 2023: $697 · 2024: $559 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,201.49 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,246.90 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $636.76 | 2021-2024 | |
| Gilead Sciences, INC. | $573.82 | 2022-2025 | Vemlidy |
| Kowa Pharmaceuticals America, INC. | $73.47 | 2025 | Zoryve |
| Amarin Pharma, INC. | $55.25 | 2022-2023 | |
| Amgen INC. | $54.71 | 2024-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $42.05 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $41.69 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Horizon Therapeutics Plc | $26.03 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.42 | 2025 | Jardiance |
| Exact Sciences Corporation | $23.84 | 2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $22.61 | 2025 | |
| Seqirus USA INC | $20.29 | 2024 | Flucelvax, Fluad |
| Glaxosmithkline, LLC. | $18.01 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Moy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.